Racial differences in susceptibility and progression of pancreatitis have been reported in epidemiologic studies using administrative or retrospective data. There has been little study, however, on the clinical profi le, causes, and outcome of chronic pancreatitis (CP) in black patients.
INTRODUCTION
Chronic pancreatitis (CP) is a chronic irreversible infl ammatory process with many underlying etiologies, treatments, and outcomes. While relatively uncommon, the disease results in signifi cant health-care expenditures with aggregate costs of over 150 million dollars yearly ( 1 ) . Th e cardinal manifestation is abdominal pain that is typically chronic, characteristically severe and unremitting, and associated with signifi cant morbidity leading to a severely reduced quality of life ( 2, 3 ) . Recent studies have expanded the causes of CP to genetic causes as well as to the important role of tobacco use (4) (5) (6) . Th e majority of these studies, however, have focused on Caucasians, typically males.
Several observations, including our own, have highlighted racial diff erences in the epidemiology of pancreatitis. Specifi cally, the risk of hospitalization for pancreatitis in black subjects has been noted to be 2-3 times greater when compared with whites (7) (8) (9) (10) , black patients with pancreatitis have a higher likelihood of alcohol etiology ( 11 ) , and aft er an episode of acute pancreatitis (AP), they are noted to have a greater risk for readmissions ( 12 ) , as well as higher rates of AP on CP and extrapancreatic manifestations of AP ( 13 ) . Unfortunately, many of these studies are retrospective, or, have used administrative data, which are limited by lack of validation or detailed information on disease phenotype and outcomes. Although the importance of these data cannot be discounted, studies with large number of blacks with patient level data are needed to characterize the clinical profi le, causes, treatment, and outcome of CP in this subgroup, and to determine whether and how they diff er from the large body of knowledge in white subjects. Such information is critical to perform more focused evaluation, plan treatments, and provide individualized counseling in black patients with CP.
In a series of multicenter studies conducted by the North American Pancreatitis Study Group from 2000 to 2014, 248 African-American (AA) patients with CP have been prospectively ascertained with deep phenotyping and collection of data on environmental exposures, clinical symptoms including pain experience, and treatments delivered. Th e aim of our study was to defi ne the clinical profi le, causes, and outcome of CP in black patients, and to compare them with over 900 white subjects enrolled in these studies. Th rough this analysis, we hoped to explore potential pathophysiologic diff erences to better our understanding of CP in this demographic group.
METHODS

North American Pancreatitis Study 2 studies
Between 2000 and 2014, the North American Pancreatitis Study group conducted three sequential studies (North American Pancreatitis Study 2 (NAPS2), NAPS2 continuation and validation study (NAPS2-CV), and NAPS2 Ancillary study (NAPS2-AS)) to prospectively ascertain patients with recurrent acute pancreatitis (RAP), CP, and controls (related, family, unrelated) subjects with an overarching goal to understand the role of genetic and environmental factors in the susceptibility and progression of pancreatitis ( Supplementary Table 1 ). Detailed methods of the original NAPS2 and NAPS2-CV studies have been published ( 14, 15 ) . Since the proportion of blacks in these two studies was few (7 and 8% respectively), the NAPS2-AS study was undertaken to specifi cally recruit AA subjects. Two centers (Johns Hopkins and University of Chicago) with a higher volume of black subjects were asked to participate in the NAPS-AS study, and thus they only recruited black subjects. Overall, 27 centers participated in at least one of the NAPS2 studies, of which one center only contributed control subjects. At the end of enrollment in 2014, the number of RAP, CP, and control subjects enrolled in the NAPS2 studies was 569, 1,195 and 1,109, respectively, and had clinical data for analysis. Th e study was approved by the Institutional Review Board at each participating center and all patients provided informed consent before enrollment.
Patient cohort for the current study
Th e present study included 248 black and 911 white subjects with CP enrolled in the NAPS2 studies that also had clinical data available for analysis. Supplementary Table 1 shows detailed information on the number of participating centers and CP patients enrolled in individual NAPS2 studies. CP was defi ned by the presence of defi nitive changes on imaging studies-computerized tomography scan, magnetic resonance imaging/magnetic resonance cholangiopancreatography, endoscopic retrograde cholangiopancreatography (Cambridge classifi cation), or endoscopic ultrasound (presence of 5 or more fi ndings or presence of calcifi cations) or histology. Disease duration was defi ned as age at enrollment minus earliest age at fi rst attack of pancreatitis or the development of symptoms compatible with CP according to physician reporting.
Questionnaires
Th e NAPS2 studies used two sets of questionnaires to collect detailed information from study subjects (administered by a trained study coordinator) and the enrolling physicians. As reported previously, patient questionnaires collected information on demographics, personal and family history, exposure to alcohol and tobacco, pain experience, quality of life, and medication use. Th e enrolling physician provided information on disease phenotype including information on history and age at fi rst episode of AP, age at onset of symptoms and diagnosis of CP, pain patterns, exocrine and endocrine insuffi ciency, the most likely etiology, TIGAR-O risk factors ( 16 ), fi ndings on imaging studies, treatments tried, and their perceived eff ectiveness. Based on experience gained from the initial NAPS2 study, some data elements in the questionnaires used for the NAPS2-CV study were modifi ed, as previously described ( 15 ) . Th e NAPS2-AS study used questionnaires similar to those of the NAPS2-CV study.
In the original NAPS2 study, patients were asked to choose from fi ve patterns of descriptions that best characterized their pain experience. No leading question was used before asking the pain pattern (i.e., do you have pain from pancreatitis?). A subset of CP patients in this study (126/540, 23%) did not complete the question on pain pattern. Due to this, it is diffi cult to know whether they had "no pain" or their pain experience did not fi t into the PANCREAS AND BILIARY TRACT VOLUME 111 | OCTOBER 2016
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fi ve predefi ned categories ( 2 ) . In the NAPS2-CV and NAPS2-AS studies, a leading question was given (Have you had abdominal pain from pancreatitis in the past year?). Patients who responded "yes" to this question were then asked to choose from one of the fi ve patterns of pain description that best characterizes their pain experience. To appropriately compare the presence of pain and the pain pattern, we limited analyses for the presence of pain, pain patterns, and pain medication use to only the NAPS2-CV and NAPS2-AS studies.
Data elements
For this study, we analyzed data on demographic factors, age of onset of symptoms, diagnosis, and enrollment, body mass index (BMI) (maximum during lifetime and at the time of enrollment), physician-defi ned etiology, TIGAR-O risk factors identifi ed by the enrolling physician, presence and pattern of pain in the year preceding enrollment as reported by the patient, use of pain medication as identifi ed by the enrolling physician, morphological changes in the pancreas on imaging studies, exocrine and endocrine insuffi ciency, treatments used, and their perceived eff ectiveness according to the enrolling physician.
Statistics
Descriptive analyses are presented as proportions for categorical data and median and interquartile range for continuous data. Bivariate comparisons were performed based on race using Fischer's exact test for categorical data and Student's t -test for continuous data. A priori data were analyzed both before and aft er stratifi cation by physician-defi ned etiology. We used logistic regression to control for center, age, and sex for our primary observed associations. Separate models were fi t including all centers and only the top three recruiting centers as sensitivity analysis. To evaluate whether the observed associations diff ered by center, we added an interaction term between race and center. We excluded centers with only 1 or 0 black or white patients from the models with the interaction term.
Data analysis was performed using SAS version 9.4 (Cary, NC). Two-tailed P values <0.05 were considered as statistically significant. Owing to the exploratory nature of this study, no adjustments were made for multiple comparisons.
RESULTS
Demographic factors and disease onset
Over the study period, 1,159 white or black CP patients were enrolled into the NAPS2 studies, of whom 248 (21%) were black. Th e percentage of black patients by study centers that enrolled ≥25 CP patients is shown in Figure 1 . Johns Hopkins participated only in the NAPS2-AS study, so all enrollees from this center were black. Among other centers, the proportion of black patients ranged from <5% (Dartmouth-Hitchcock, Lebanon, NH and Mayo Clinic, Jacksonville, FL) to 45-50% (Virginia Commonwealth University, Richmond, VA and University of Alabama, Birmingham, AL). Baseline demographics of the cohort by race are provided in Table 1 . As shown, when compared with whites, black patients were signifi cantly more likely to be male (60.9 vs. 53%). Th e median age of black and white subjects was similar at 53.3 and 51.5 years, respectively. However, their age distribution at the time of enrollment diff ered from whites, in that two-thirds of black subjects were middle aged (i.e., 44-65 years) as compared with a broader distribution of age groups among whites. Th e age at onset of pancreatitis symptoms, age at diagnosis, and a history of AP were similar in the two races. BMI at the time of enrollment was signifi cantly lower in blacks when compared with whites (22.9 vs. 24.1). Blacks were more likely to have ever smoked (88.2 vs. 71.8%) and two-thirds of them were current smokers at the time of enrollment. Interestingly, the amount of tobacco use was signifi cantly lower in blacks when compared with whites. Among ever-smokers who reported their amount of smoking, whites were 1.8 times more likely to be heavy smokers (i.e., ≥1 p.p.d.) when compared with blacks (RR 1.84, P <0.05).
Cause of pancreatitis
As shown in Tables 2 and 3 , physician-defi ned etiology and risk factors between the races were signifi cantly diff erent. Physicians identifi ed alcohol as the etiology of CP in the majority of blacks ((77 vs. 42%; RR 1.84, P <0.05)). In contrast, other etiologies including genetic (10.2 vs. 1.6%), obstructive (7.9 vs. 2.4%), idio pathic (27.8 vs. 12.9%), and autoimmune (2.6 vs. 0%) were identifi ed by physicians signifi cantly more oft en in whites.
Based upon the TIGAR-O classifi cation, physicians identifi ed tobacco as a risk factor more oft en in blacks than in whites (73.4 vs. 43.4%). To evaluate whether this eff ect was due to a higher prevalence of smoking in blacks, we limited this analysis only to subjects who were self-reported smokers. Interestingly, among these subjects also, physicians identifi ed tobacco as a risk factor in a higher fraction of blacks when compared with whites (82.7 vs. 59.4%). Similar to etiology, obstructive causes were signifi cantly diff erent 
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Race and Chronic Pancreatitis between the groups with obstruction of some type reported as a risk factor in 20.8% of whites as compared with 10.1% of blacks ( P <0.05). Pancreas divisum was listed in 10.2% of whites as compared with 4.8% of blacks. Likewise, sphincter of Oddi dysfunction was attributed in 5.7% of whites as compared with 1.6% of blacks. When data were analyzed aft er further stratifi cation by sex, alcohol and tobacco smoking remained the most frequently identifi ed causes and risk factors for CP in both black men and women, and these were signifi cantly diff erent from white men and women, respectively (data not shown). To determine whether the prevalence and intensity of smoking based on race was limited to CP patients, we evaluated the prevalence of smoking in controls enrolled in the NAPS2 studies. Th e prevalence of ever smoking was similar (50 vs. 51%), current smoking was higher (31 vs. 20%), heavy smoking (>=1 ppd) overall was lower (8 vs. 23%) in black controls when compared with white controls.
However, when comparing controls vs. CP patients, the relative risk of being a heavy smoker overall was higher (3.43 vs. 1.76 times) among blacks CP vs. controls (27.5 vs. 8%) when compared with whites CP vs. controls (40.5 vs. 23%). Th ese fi ndings suggest that being a heavy smoker is a stronger risk factor for CP in the black population compared with the white population.
To address the eff ect of center on the primary observations (alcohol, tobacco), we have performed logistic regression analyses where we used the status of etiology or primary risk factors under investigation as the outcome variable (physician-defi ned alcohol etiology; patient reported heavy or very heavy drinking; physician identifi cation of tobacco as risk factor; patient reported smoking status-yes vs. no) and center as one of the covariates. We tested the interaction between race and center in these regression models. Th ese models were applied to data from all centers with at least two white and two black patients recruited (15/26 centers) and data from the top three centers as sensitivity analysis. In these analyses, the interaction terms between centers and race were not statistically signifi cant (range of P values: 0.054-0.979), suggesting that the observed association between race and alcohol and tobacco was not related to centers.
Because the interaction term in these models was not significant we dropped the interaction term and included all 26 centers in the "all centers" model in the results below ( Table 4 ) . We found that the odds for black patients for alcohol exposure or etiology, and tobacco exposure or risk factor was signifi cantly higher when compared with white patients, controlling for center, age, and sex. irregularities (45.6 vs. 24%) when compared with whites, with no diff erence noted for other morphological features. Similar to morphological changes, blacks were more likely to have endocrine insuffi ciency (35.1 vs. 21.4%, P <0.04), a diff erence that continued to be seen aft er stratifi cation in blacks with alcoholic CP but not with other etiologies. No diff erences were observed in the prevalence of exocrine insuffi ciency between the races.
Th ese diff erences in part were explained by longer duration of disease in blacks when compared with whites, which showed a trend for all patients (8.21±8.28 vs. 7.25±7.62, P =0.10), and signifi cant results for alcoholic CP (8.6±8.41 vs. 6.97±7.07, P =0.02).
Pain, pain patterns, narcotic use, and disability
Overall, in the NAPS2-CV and NAPS2-AS studies, 556/643 (86.5%) patients reported having pain related to CP in the year preceding enrollment. Important diff erences were detected in pain experience based on race. Black patients were signifi cantly ( P <0.05) more likely to report any pain (94.7 vs. 83%), constant pain (62.6 vs. 51%), and severe pain (78.4 vs. 65.8%) when compared with whites. Th ese diff erences persisted aft er stratifi cation of patients by etiology ( Table 6 ). Roughly, ~80% patients who reported having pain in the preceding year were on pain medications (non-narcotic or narcotic). Th e proportion of patients with pain using any pain medication or narcotic medications was statistically higher in blacks, overall and aft er stratifi cation by alcohol etiology. Greater than one-third of black patients reported being disabled due to CP, which was signifi cantly higher when compared with whites (21%, RR 1.64, P <0.05), irrespective of etiology.
Analysis was also performed stratifying patients based upon a median duration of disease (less or greater than 4.55 years). Th is analysis demonstrated persistence of racial diff erences for many of these morphological features as well as pain. Specifi cally, among patients with a duration of disease >4.55 years, blacks were still statistically more likely than whites to have calcifi cations ( P <0.001),
Morphology, exocrine, and endocrine insuffi ciency
Many signifi cant diff erences were noted in the morphological appearance of the pancreas in blacks when compared with whites on imaging studies. Overall, blacks had a signifi cantly higher prevalence ( P <0.05) of calcifi cations (63.3 vs. 55.2%), pancreatic atrophy (43.2 vs. 34.6%), pancreatic ductal strictures or dilatation (72.6 vs. 65.5%), pancreatic duct irregularities (52.4 vs. 24.2%), common bile duct dilatation (24.6 vs. 13.7%), or stricture (18.6 vs. 8.2%) when compared with whites ( Table 5 ) . Th e prevalence of each of these morphological fi ndings was also signifi cantly higher in black patients with alcoholic pancreatitis, suggesting that these fi ndings were attributable to diff erences between the morphologic abnormalities in black vs. white patients with alcoholic CP. Aft er stratifi cation by alcohol etiology, blacks with non-alcoholic etio logies were signifi cantly less likely to have calcifi cations (28.8 vs. 50.4%) and had a higher prevalence of pancreatic duct pseudocyst at anytime ( P =005), atrophy ( P =0.03), and diabetes (0.02). Prevalence of ductal irregularities and CBD strictures ( P <0.05 for both) was signifi cantly more common in blacks irrespective of disease duration, while ductal dilatation or strictures and CBD dilatation were signifi cantly more common in blacks with disease duration of <4.55 years. Th e prevalence of disability increases in both races with disease duration, but was signifi cantly higher in blacks when compared with whites for disease duration <4.55 years (27.9 vs. 16.5%, P =0.007) and >4.55 years (41.9 vs. 26.7%, P =0.002). Diff erences in the prevalence of pain persisted among between races for no pain ( P =0.007) and severe pain ( P =0.006) for disease duration <4.55 years, and for constant pain ( P =0.005) for duration of >4.55 years.
Therapies
Th e use of medical, endoscopic, or surgical therapies was not diff erent between the two races, overall and aft er stratifi cation of alcohol etiology ( Table 7 ) , except for cholecystectomy that had been performed in a higher percentage of white patients when compared with blacks (31.1 vs. 19%, P <0.05). Th e majority of patients were taking oral pancreatic enzyme replacement therapy (66.8%). Celiac nerve block was infrequently used across Table 5 . Morphological features, exocrine and endocrine insuffi ciency, and disability by race among subjects with chronic pancreatitis and CFTR), as these have not been shown to increase the risk of alcoholic pancreatitis ( 6 ) . In two recent genome-wide association studies, polymorphisms at the claudin locus were found to increase the risk of alcoholic pancreatitis-but, both of these studies were limited to Caucasian patients of European descent. Whether this fi nding is merely a refl ection of a higher prevalence of alcohol consumption in black patients or is a result of their increased susceptibility to pancreatitis from alcohol exposure deserves further evaluation with focused genetic studies. Black patients also had a higher prevalence of ever and current smoking, which are now accepted as a risk factor for susceptibility to and progression of pancreatitis. Interestingly, the intensity of smoking was greater among whites, an observation that has also been noted in the general population ( 17 ) . Th e diff erence we detected between blacks and whites regarding heavy smoking also suggests this to be a greater risk factor for CP in blacks. Explanation for the morphologic diff erences identifi ed between the two races is speculative. Th ese diff erences were explained in part by underlying cause and duration of disease in stratifi ed analysis. Calcifi cations were more common in blacks than in white patients both overall and in those with alcohol etiology. Alcoholinduced CP is characteristically associated with calcifi cations ( 18 ) . Prior studies suggest that smoking is commonly associated with pancreatic calcifi cations ( 19, 20 ) and with continued smoking once the diagnosis of CP is made, these pancreatic calcifi cations typically progress ( 21 ) . Whether the combination of tobacco and alcohol or some other genetic factor(s) has a role in the greater rate of calcifi cations and other morphological fi ndings we identifi ed among blacks is unknown. Given that both alcohol ( 22 ) and smoking ( 23 ) adversely aff ect CFTR localization and CFTR all patients. Also, endoscopic therapy overall was used in 50% of patients and surgical treatment other than cholecystectomy had been undertaken in 20% of patients.
DISCUSSION
Th is is the fi rst comprehensive study of the clinical profi le of CP in a well-phenotyped prospectively ascertained cohort of black patients in the United States. We found that when compared with whites, black patients were almost twice as likely to be diagnosed to have CP due to alcohol or smoking; more likely to have morphologic abnormalities of the pancreas; more likely to have, and describe their pain as constant or severe; have a higher prevalence of endocrine insuffi ciency; and have a greater degree of disease-related disability. No clinically important diff erences were observed in treatment based on race other than higher frequency of cholecystectomy among white patients. Some of these racial diff erences could be explained by the higher prevalence of environmental exposures in black CP patients.
We confi rm prior reports of a higher prevalence of physiciandefi ned alcohol etiology, and cigarette smoking in black patients. In fact, physicians identifi ed alcohol as the risk factor for CP in as many as 80%, tobacco smoking in 73%, and either of these two habits in 87% of all black patients. As an independent measure of alcohol exposure, we evaluated drinking categories based on selfreported data from patients and found that black patients had a signifi cantly higher prevalence of very heavy or heavy drinking when compared with white patients (69 vs. 41%, P <0.05). A higher prevalence of alcohol etiology in blacks cannot be explained by the established genetic susceptibility factors (PRSS1, CTRC, SPINK1, 
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Race and Chronic Pancreatitis mislocalization results in formation of pancreatic stone formation ( 24 ) , the increased levels of alcohol and smoking in black patients, compared with white patients may be a potential explanation for their increased prevalence of calcifi cations. Black patients also had a higher prevalence of endocrine insuffi ciency. Th e explanation of this fi nding is likely multifactorial and includes a higher prevalence of alcohol and tobacco exposure, more advanced morphological fi ndings, and a higher risk of diabetes in blacks. Th e most important symptom of CP is abdominal pain, which strongly impacts quality of life ( 2 ) . Th ese data demonstrate diff erences among the races in the presence, character, and quality of pain. Black patients were almost twice as likely to have their pain described as constant and only 5% had no abdominal pain. Severe pain was much more likely in blacks than in whites and perhaps this is related to underlying causes of alcohol and tobacco. Prior studies have not shown diff erences in pain response based upon race per se ( 25 ) . Alcohol-induced CP may be linked to greater degrees of pain. Further work would be required to diff erentiate any diff erences in pain response in CP based upon race.
Several limitations of our study deserve mention. Our study was a cross-sectional study and thus long-term follow-up to evaluate for diff erences over time and mortality could not be performed. Other issues related to outcome including access to and use of outpatient or inpatient resources before diagnosis and until enrollment were not captured. Health-care access is important as it is clearly recognized that early alcohol and perhaps smoking cessation counseling can prevent recurrent pancreatitis and potential progression to CP ( 26, 27 ) . Potential disparities in health-care access based on race will need to be further explored given the signifi cantly higher rates of alcohol and tobacco use as well as disability in black compared with white CP patients. We also found a discrepancy between patient reported and physician reported alcohol use more oft en in black than in white patients. Whether this represents some inherent bias regarding cause by physicians is unknown or is an important fi nding requires further study. Our data were generated primarily from academic medical centers and thus may not be applicable to community patients. Our study focused on patients with a defi nite diagnosis of CP. Th erefore, we were unable to evaluate whether there are racial diff erences in the evaluation of patients who present with symptoms suggestive of CP.
In summary, we identifi ed relevant and signifi cant diff erences among black and white patients with CP. Alcohol and tobacco use were far more likely in black than in white patients and these were also associated with greater rates of morphologic abnormalities, more constant and severe pain, endocrine insuffi ciency as well as disability. Additional research will be required to determine whether any greater genetic susceptibility to alcohol and/or tobacco induced disease and other features of CP is present based upon race. 
Study Highlights
WHAT
WHAT IS NEW HERE
✓ As compared with whites, blacks were almost twice as likely to have alcohol as a cause of disease.
✓ Advanced morphological abnormalities including calcifi cations, atrophy, and ductal strictures were signifi cantly more common in blacks than in whites.
✓ Abdominal pain was more common, more severe, and more likely to result in disability in blacks as compared with whites.
